R&D expenses of Moderna by type 2023
In 2023, Moderna spent some 2.34 billion U.S. dollars on infectious disease vaccines as part of its research and development expenses. The statistic illustrates the research and development expenses of Moderna Inc. in 2023, by type. Moderna became well-known for its COVID-19 vaccine Spikevax (mRNA-1273), one of the very first vaccines to be developed and approved for widely usage.